Applying genome-wide CRISPR-Cas9 screens for therapeutic discovery in facioscapulohumeral muscular dystrophy
- 25 March 2020
- journal article
- research article
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 12 (536)
- https://doi.org/10.1126/scitranslmed.aay0271
Abstract
The emergence of CRISPR-Cas9 gene-editing technologies and genome-wide CRISPR-Cas9 libraries enables efficient unbiased genetic screening that can accelerate the process of therapeutic discovery for genetic disorders. Here, we demonstrate the utility of a genome-wide CRISPR-Cas9 loss-of-function library to identify therapeutic targets for facioscapulohumeral muscular dystrophy (FSHD), a genetically complex type of muscular dystrophy for which there is currently no treatment. In FSHD, both genetic and epigenetic changes lead to misexpression of DUX4, the FSHD causal gene that encodes the highly cytotoxic DUX4 protein. We performed a genome-wide CRISPR-Cas9 screen to identify genes whose loss-of-function conferred survival when DUX4 was expressed in muscle cells. Genes emerging from our screen illuminated a pathogenic link to the cellular hypoxia response, which was revealed to be the main driver of DUX4-induced cell death. Application of hypoxia signaling inhibitors resulted in increased DUX4 protein turnover and subsequent reduction of the cellular hypoxia response and cell death. In addition, these compounds proved successful in reducing FSHD disease biomarkers in patient myogenic lines, as well as improving structural and functional properties in two zebrafish models of FSHD. Our genome-wide perturbation of pathways affecting DUX4 expression has provided insight into key drivers of DUX4-induced pathogenesis and has identified existing compounds with potential therapeutic benefit for FSHD. Our experimental approach presents an accelerated paradigm toward mechanistic understanding and therapeutic discovery of a complex genetic disease, which may be translatable to other diseases with well-established phenotypic selection assays.Keywords
This publication has 73 references indexed in Scilit:
- Digenic inheritance of an SMCHD1 mutation and an FSHD-permissive D4Z4 allele causes facioscapulohumeral muscular dystrophy type 2Nature Genetics, 2012
- Transcriptional profiling in facioscapulohumeral muscular dystrophy to identify candidate biomarkersProceedings of the National Academy of Sciences of the United States of America, 2012
- Attachment ofChlamydia trachomatisL2 to host cells requires sulfationProceedings of the National Academy of Sciences of the United States of America, 2012
- DUX4 Activates Germline Genes, Retroelements, and Immune Mediators: Implications for Facioscapulohumeral DystrophyDevelopmental Cell, 2012
- Hypoxia-Inducible Factors and the Response to Hypoxic StressMolecular Cell, 2010
- The GeneMANIA prediction server: biological network integration for gene prioritization and predicting gene functionNucleic Acids Research, 2010
- Identification of small molecule compounds that inhibit the HIF-1 signaling pathwayMolecular Cancer, 2009
- An isogenetic myoblast expression screen identifies DUX4-mediated FSHD-associated molecular pathologiesThe EMBO Journal, 2008
- DUX4 , a candidate gene of facioscapulohumeral muscular dystrophy, encodes a transcriptional activator of PITX1Proceedings of the National Academy of Sciences of the United States of America, 2007
- Hypoxia — a key regulatory factor in tumour growthNature Reviews Cancer, 2002